This segment brings together two essential threads — the broader context of lorlatinib's remarkable durability relative to ...

Kutscher says MDVIP is expanding into specialty care and eyeing pediatrics. Your browser does not support the audio element.

This segment addresses one of the most practically important aspects of lorlatinib therapy — its distinct and manageable ...

Hofstra University and Northwell Health’s jointly founded medical school has secured funding from the National Institutes of ...

Positive symptoms correlated with more negative sentiment and longer utterances, whereas negative symptoms aligned with ...

FDA approved veligrotug-vvze for TED regardless of activity or duration, using a 12-week course of five IV infusions administered every three weeks. Pivotal THRIVE/THRIVE-2 trials met primary and all ...

The healthcare industry succeeded in making behavioral healthcare more accessible, argues Machinify's Lisa Pincher. Now, it must build the infrastructure to support that care responsibly. What happens ...

Lung cancer has shifted from a rare, smoking-driven disease to one increasingly seen in young non-smokers, especially women, with possible links to pesticide exposure from otherwise “healthy” diets.

Reconstructed IPD meta-analysis showed chemoimmunotherapy improved OS and PFS versus PD-(L)1 monotherapy within PD-L1–high disease, with consistent findings across multiple analytic approaches and ...

Financial sustainability and innovation are interdependent, as clinician-led contracting strategies that improve outcomes generate savings that fund further innovation. Balancing innovation and ...

In SYNCHRONIZE-MASLD (n=218), 84.2% on weekly survodutide 6.0 mg achieved ≥30% relative liver fat reduction versus 24.3% with placebo at week 48. Liver fat normalization occurred in ~61% of ...